Women with HIV can now add to their Pap smears another crucial earlywarning system for cervical cancer. The FDA has approved atest—Digene’s Hybrid Capture II—to spot all 13 forms of the humanpapilloma virus (HPV) that is associated with this cancer. HPV’spresence makes HIVers four to five times more likely than HIV negativewomen to develop dysplasia—the cell abnormality that precedes cervicalcancer. Using the Hybrid Capture II test to identify who is infectedwith a cancer-promoting strain of virus could prompt closer screeningfor dysplasia and earlier treatment—and help prevent full-blown cancer.